Market Research Logo

FirstWord

FirstWord belongs to a business group that forms one of the world's largest healthcare knowledge networks. Drawing from these knowledge assets, FirstWord reports deliver insight, analysis and the latest thinking on important trends and the most challenging issues affecting the pharmaceutical industry today. Highly-focused, relevant, up-to-date, actionable intelligence - reports that deliver vital intelligence to give a competitive edge.
...Show More ...Show Less

483 Reports from FirstWord

   
  • Medical Affairs Reputations: Renal Cell Carcinoma (US) 2018

    ... rival. The 100 medical oncologists we polled say that each of those teams needs improvement in at least one specific area, but are those targeted improvements enough to put your team ahead of the competition? ... Read More

  • Market Access Impact: HIV (EU5) 2018

    ... HIV prescriptions, no single brand has a significant lead over other brands. Market share for all players is up for grabs! Find out what’s driving share gains, and what your brand can do to level ... Read More

  • NPS+ Hepatitis C Virus (HCV) Infection US [2018]

    ... some of these options are achieving greater levels of loyalty and satisfaction than others – but why? What are the key factors driving physician choice and how does each of the leading brands compare to ... Read More

  • Biosimilars: EU Payer Perspectives

    ... $232 billion global biologics market is now seriously under threat. New biosimilar entrants have been taking on the European biologic brands for the last decade. The difference is: now they're winning. Are you keeping up ... Read More

  • Market Access Impact: Melanoma (US) 2018

    ... has a significant lead over all other brands. Find out what’s driving its share gains, and what your brand can do to level the playing field in Market Access Impact: Melanoma (US) [2018]. Based on ... Read More

  • NPS+ Renal Cell Carcinoma (US) 2018

    ... levels of loyalty and satisfaction than others – but why? What are the key factors driving physician choice and how does each of the leading brands compare to its competitors? NPS+ RCC (US) gives a ... Read More

  • NPS+ Renal Cell Carcinoma (EU5) 2018

    ... levels of loyalty and satisfaction than others – but why? What are the key factors driving physician choice and how does each of the leading brands compare to its competitors? NPS+ RCC (EU5) gives a ... Read More

  • NPS+ Hepatitis C Virus (HCV)Infection (EU5) [2018]

    ... some of these options are achieving greater levels of loyalty and satisfaction than others – but why? What are the key factors driving physician choice and how does each of the leading brands compare to ... Read More

  • Medical Affairs Reputations: Non-Small Cell Lung Carcinoma (EU5) 2018

    ... with at least one rival. The 150 medical oncologists we polled say that nearly every team needs improvement in two or more areas, but are those targeted improvements enough to put your team ahead of ... Read More

  • Medical Affairs Reputations: Psoriasis (EU5) 2018

    ... with at least one rival. The 150 dermatologists we polled say that nearly every team needs improvement in two or more areas, but are those targeted improvements enough to put your team ahead of the ... Read More

  • Bladder Cancer: Update Bulletin #2 [February 2018]

    ... from a Phase I/II study investigating a combination of its PD-1 inhibitor Opdivo (nivolumab) with its pipeline indoleamine 2,3-dioxygenase 1 (IDO1) inhibitor, BMS-986205, in heavily pretreated patients with advanced bladder cancer; BioCanCell announcing final results ... Read More

  • Chronic lymphocytic leukemia (CLL): Update Bulletin #2

    ... III study of AbbVie/Roche’s Venclexta/Venclyxto (venetoclax) in combination with Rituxan/MabThera (rituximab; Roche) presented at the ASH meeting in December 2017; the initiation of a Phase III study investigating BeiGene’s novel Bruton’s tyrosine kinase (BTK) inhibitor ... Read More

  • Non Small Cell Lung Cancer (NSCLC): Update Bulletin #2

    ... of the Phase III KEYNOTE-189 trial of Merck & Co.’s Keytruda (pembrolizumab), in combination with chemotherapy, for the first-line treatment of patients with metastatic NSCLC in meeting its co-primary endpoints of overall survival (OS) and ... Read More

  • Nonalcoholic Steatohepatitis (NASH): Update Bulletin

    ... market, including; Intercept Pharmaceuticals announcing the initiation of the global Phase III REVERSE study to evaluate the efficacy and safety of obeticholic acid (OCA; Ocaliva); Madrigal Pharmaceuticals reports positive top-line data from a Phase II ... Read More

  • NPS+ HIV (US) 2018

    ... achieving greater levels of loyalty and satisfaction than others – but why? What are the key factors driving physician choice and how does each of the leading brands compare to its competitors? NPS+ HIV (US) ... Read More

  • Breast Cancer: Update Bulletin #3

    ... FDA approval of Lynparza (olaparib; AstraZeneca) for patients with metastatic BC with BRCA gene mutation; Pfizer’s talazoparib EMBRACA Phase III data in patients with advanced or metastatic BC; as well as Syndax Pharmaceuticals announcing a ... Read More

  • Medical Affairs Reputations: Non-Small Cell Lung Carcinoma (US) 2018

    ... with at least one rival. The 100 medical oncologists we polled say that each of those teams needs improvement in at least one specific area, but are those targeted improvements enough to put your team ... Read More

  • Medical Affairs Reputations: Psoriasis (US) 2018

    ... with at least one rival. The 100 dermatologists we polled say that each of those teams needs improvement in at least one specific area, but are those targeted improvements enough to put your team ahead ... Read More

  • Market Access Impact: Melanoma (EU5) 2018

    ... two rivals that are in 2nd and 3rd place. Find out how eliminating barriers would shake up the top and middle of the market, and help the last place brand double its share in Market ... Read More

  • NPS+ Haemophilia B (EU5) 2018

    ... are achieving greater levels of loyalty and satisfaction than others – but why? What are the key factors driving physician choice and how does each of the leading brands compare to its competitors? NPS+ Haemophilia ... Read More

  • Medical Affairs Reputations: Type 2 Diabetes Mellitus [Orals] (EU5) 2018

    ... of the Type 2 Diabetes Mellitus medical affairs teams we surveyed are running neck and neck with at least one rival. The 150 diabetologists we polled say that nearly every team needs improvement in two ... Read More

  • Medical Affairs Reputations: Type 2 Diabetes Mellitus [Orals] (US) 2018

    ... of the medical affairs teams focused on oral Type 2 Diabetes Mellitus therapies which we surveyed are running neck and neck with at least one rival. The 100 diabetologists we polled say that each of ... Read More

  • Malignant Melanoma: Update Bulletin

    ... Merck & Co.) as monotherapy for patients with surgically resected high-risk melanoma; views on the potential of Idera Pharmaceuticals’ IMO-2125, which has been granted Fast Track designation by the FDA in combination with ipilimumab for ... Read More

  • Market Access Impact: Ulcerative Colitis (EU5) 2018

    ... the top brand way ahead of its two rivals that are in 2nd and 3rd place. Find out how eliminating barriers would shake up the top and middle of the market, and help the last ... Read More

  • Market Access Impact: Ulcerative Colitis (US) 2018

    ... the top two brands have a significant lead over all other brands. Find out what’s driving its share gains, and what your brand can do to level the playing field in Market Access Impact: Ulcerative ... Read More

1 3 5 6 7 8 9 10

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook